Hemostemix Inc
เพิ่มขึ้น

$HMTXF - Stock Price is Hike on OTC Market


Hemostemix is an autologous stem cell therapy company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company developed and is commercializing its lead product ACP-01 for the treatment of CLI, PAD, Angina, Ischemic Cardiomyopathy, Dilated Cardiomyopathy and other conditions of ischemia. As per HMTXF current market analysis price is 0.24445 upgraded in 3.76% and daily range 0.24445 - 0.2508
Fundamental AnalysisTechnical IndicatorsTrend Analysis

และใน:

คำจำกัดสิทธิ์ความรับผิดชอบ